TopoTarget A/S
TopoTarget (CSE: TOPO) is a fully integrated biopharmaceutical company with facilities in Denmark, UK and Germany dedicated to finding ‘’Answers for Cancer’’ The company combines in-depth understanding of the molecular mechanisms of cancer with broad experience from clinical cancer practice and has developed highly predictive cancer models. The platform covers key cancer enzyme regulators (mainly HDAC and topoisomerase II inhibitors) and a broad portfolio of small molecule preclinical drug candidates has been built. TopoTarget has eight drugs in clinical development, consisting of both novel anti-cancer therapeutics and new cancer indications for existing drugs. The most advanced drug candidate, Savene™ for extravasations is expected to be launched in the US and Europe end 2006. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing.
TopoTarget (CSE: TOPO) is a fully integrated biopharmaceutical company with facilities in Denmark, UK and Germany dedicated to finding ‘’Answers for Cancer’’ The company combines in-depth understanding of the molecular mechanisms of cancer with broad experience from clinical cancer practice and has developed highly predictive cancer models. The platform covers key cancer enzyme regulators (mainly HDAC and topoisomerase II inhibitors) and a broad portfolio of small molecule preclinical drug candidates has been built. TopoTarget has eight drugs in clinical development, consisting of both novel anti-cancer therapeutics and new cancer indications for existing drugs. The most advanced drug candidate, Savene™ for extravasations is expected to be launched in the US and Europe end 2006. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing.